Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × enzalutamide × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 76 Breast Neoplasms 10 Neoplasm Metastasis 7 Prostatic Neoplasms, Castration-Resistant 4 Prostate Cancer Metastatic 4 Neoplasms 4 Metastatic Castration-Resistant Prostate Cancer 4 Triple Negative Breast Neoplasms 2 Metastatic Castration-resistant Prostate Cancer 2 Castration-resistant Prostate Cancer 2 Castration Resistant Metastatic Prostate Cancer 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Salivary Cancer 1 Recurrent Endometrial Endometrioid Adenocarcinoma 1 Prostate Carcinoma Metastatic to the Bone 1 Prostate Adenocarcinoma 1 Primary Breast Cancer ER+ve 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 NSCLC Harboring NRG1 Fusion 1 Metastatic Progressive Castration-resistant Prostate Cancer 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Liposarcoma 1 Hormone-refractory Prostate Cancer 1 Colorectal Neoplasms 1

Interventions

Oxaliplatin 26 Gemcitabine 22 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 14 Docetaxel 13 Cisplatin 13 Bevacizumab 12 Radiotherapy 8 Paclitaxel 7 Irinotecan 7 Trastuzumab 6 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Sunitinib 4 Metformin 4 Gefitinib 4 Erlotinib Hydrochloride 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Ramucirumab 3 Nivolumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06844383 2025-10-29

TALENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡